Treatment of cockroach allergen asthma model with imatinib attenuates airway responses.

摘要: In the present study it was determined whether a pharmacologic approach to blocking receptor tyrosine kinase-mediated activation during allergic airway responses could be beneficial. To examine these responses, mice were given single oral dose of imatinib at clinically relevant concentrations, ranging from 0.05 50 mg/kg, by gavages just before allergen challenge. The reduction in allergen-induced significant and centered on reducing overall inflammation as well pulmonary cytokine levels. particular, treatment with significantly attenuated hyperreactivity peribronchial eosinophil accumulation, reduced Th2 cytokines, interleukin-4 interleukin-13. addition, chemokines previously associated disease, CCL2, CCL5, CCL6, lungs imatinib-treated animals. Together data demonstrate that inhibitor may provide attractive therapy for allergic, asthmatic responses.